NIH TRND program: successes in preclinical therapeutic development

Affiliations

¹ Therapeutics for Rare and Neglected Diseases (TRND) Program, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD 20850, USA. john.mckew@nih.gov

John C McKew et al. Trends Pharmacol Sci. 2013 Feb.

. 2013 Feb;34(2):87-9.

doi: 10.1016/j.tips.2012.10.001. Epub 2012 Nov 19.

¹ Therapeutics for Rare and Neglected Diseases (TRND) Program, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD 20850, USA. john.mckew@nih.gov

No abstract available

Cited by

New Financial and Research Models for Pediatric Orphan Drug Development - Focus on the NCATS TRND Program.
Shen J, Grewal G, Pilon AM, McKew JC. Shen J, et al. Pharmaceut Med. 2014 Feb 1;28(1):1-6. doi: 10.1007/s40290-014-0047-5. Pharmaceut Med. 2014. PMID: 24855373 Free PMC article.
Rare diseases research: expanding collaborative translational research opportunities.
Groft SC. Groft SC. Chest. 2013 Jul;144(1):16-23. doi: 10.1378/chest.13-0606. Chest. 2013. PMID: 23880676 Free PMC article.

1. Munos B. Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov. 2009;8(12):959–968. - PubMed
1. Paul SM, et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov. 2010;9(3):203–214. - PubMed
1. Orphan Drug Act. Public Law 97-414. United States of America; 1983.
1. Public Law 98-551. United States of America; 1984. Health Promotion and Disease Prevention Amendments of 1984.
1. Collins FS. Reengineering translational science: the time is right. Sci Transl Med. 2011;3(90):90cm17. - PMC - PubMed